Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
Imbruvica faces challenges on multiple fronts.
Can a combination approach improve the efficacy of ziftomenib in AML patients with KMT2A rearrangements?
Raludotatug deruxtecan, ABBV-383 and zongertinib advance into phase 3, while other pivotal programmes are expanded.
As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove.
Crossover hits overall survival, pouring doubts on the group’s deal hopes.